Abeona Therapeutics Inc. (NASDAQ:ABEO)’s share price traded up 1.9% during mid-day trading on Wednesday . The stock traded as high as $4.36 and last traded at $4.36, with a volume of 56,534 shares traded. The stock had previously closed at $4.28.

ABEO has been the topic of a number of recent research reports. Zacks Investment Research upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research note on Wednesday, April 27th. FBR & Co reiterated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Sunday, May 22nd. Maxim Group set a $6.00 target price on Abeona Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 18th. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $17.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, May 18th.

The firm’s 50 day moving average price is $3.11 and its 200 day moving average price is $2.79. The company’s market cap is $145.59 million.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. On average, equities analysts predict that Abeona Therapeutics Inc. will post ($0.71) EPS for the current year.

A hedge fund recently raised its stake in Abeona Therapeutics stock. Royce & Associates LLC boosted its position in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned about 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent SEC filing.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.